Associations between combinations of body mass index plus non-alcoholic fatty liver disease and diabetes mellitus among Korean adults

Asia Pacific Journal of Clinical Nutrition

Volumn 20, Issue 1, 2011, Pages 14-20

  Kim, Sang Hwan ^a   Lee, Ji Won ^b   Hwang, Hee Jin ^a  

^a Kwandong University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Body mass index; Diabetes; Fatty liver; Glucose metabolism; Obesity

Indexed keywords

ADULT; ARTICLE; BODY MASS; DIABETES MELLITUS; DIET RESTRICTION; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; OBESITY; SOUTH KOREA;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES COMPLICATIONS; DIABETES MELLITUS; FASTING; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; REPUBLIC OF KOREA;

EID: 79955731194     PISSN: 09647058     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-97.
2. Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, Dobs A, Polak JF, Savage PJ. Cardiovascular disease in older adults with glucose disorders: Comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet. 1999;354:622-5.
3. O Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther. 2003;25:1017-38.
4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.
5. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-7.
6. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124: 71-9.
7. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18:353-8.
8. Laine F, Bendavid C, Moirand R, Tessier S, Perrin M, Guillygomarch A et al. Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology. 2004;39:1639-46.
9. Seppala-Lindroos A, Vehkavaara S, Hakkienen AM, Goto T, Westerbacka J, Sovijarvi A Halavaara J, Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87:3023-8.
10. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and imparted glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-94. Diabetes Care. 1998;21: 518-24.
11. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
12. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104:861-7.
13. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al. Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-7.
14. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2004;26:3160-7.
15. Western Pacific Regional Office of the World Health Organization, the International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia; 2000.
16. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
17. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-50.
18. WPDD committee. Plan of action for the Western Pacific Declaration on Diabetes 2000~2005. Manila: World Health Organization Western Pacific Regional Office; 2001.
19. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22:1141-5.
20. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest. 2006;116:1756-60.
21. Feinleib M. Epidemiology of obesity in relation to health hazards. Ann Intern Med. 1985;103:1019-24.
22. Ohlson LO, Larsson B, Bjorntorp P, Eriksson H, Svardsudd K, Welin L, Tibblin G, Wilhelmsen L. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia. 1988;31:798-805.
23. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103-9.
24. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74-80.
25. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Path. 1989;20:594-8.
26. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107:450-5.
27. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18:353-8.
28. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183-92.
29. Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab. 2008;34:649-57.
30. Yki-Jarvinen H. Action of insulin on glucose metabolism in vivo. Baillieres Clin Endocrinol Metab. 1993;7:903-27.
31. Magnusson I, Rothman DL, Katz Ld, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest. 1992;90:1323-7.
32. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123: 745-50.